Multinational drug companies intend to expand their investments and operations in Asia in the coming months despite concerns about corruption and patents, a survey by PwC, the consultancy firm, has found.

One third of multinationals with bases in Asia intend to expand through acquisitions or by building greenfield sites in the region during the next year. Three-quarters of local pharmaceutical companies emphasise exporting outside their local market as an important goal.